Bymark Leiser News Today

CHICAGO — Zanidatamab exhibited durable antitumor activity among patients with previously treated advanced HER2-amplified biliary tract cancer, according to results of the phase 2B HERIZON-BTC-01 study presented at ASCO Annual Meeting.More than half of patients who received zanidatamb (Jazz Pharmaceuticals/Zymeworks) monotherapy survived at least a year and median OS exceeded 15 months.

CHICAGO — Trastuzumab deruxtecan extended PFS compared with standard chemotherapy for certain patients with pretreated breast cancer, according to findings presented at ASCO Annual Meeting.The analysis — which included patients with hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer that progressed after endocrine therapy — also showed considerably

CHICAGO — Comprehensive prescription drug monitoring program mandates appeared associated with a moderate reduction in the number of opioid analgesics dispensed to people dying of cancer, according to study results.Reductions were two to three times higher among non-Hispanic Black and Asian/Pacific Islander decedents than non-Hispanic white decedents, findings presented at ASCO Annual

CHICAGO — ASCO and American Cancer Society will collaborate to make it easier for patients and their caregivers to find credible cancer information online.The effort is intended to establish one of the largest, most comprehensive online sources of authoritative cancer information.

CHICAGO — High-deductible health plans appeared associated with shorter survival among cancer survivors, according to results of a nationwide population-based analysis presented at ASCO Annual Meeting.The findings suggest high-deductible health plans may create a financial disincentive for cancer survivors that prevents them from seeking necessary medical care, according to Justin Barnes,

CHICAGO — A review of more than 1,700 prior authorization requests related to pain medication for people with cancer showed the vast majority ultimately got approved.However, chart reviews documented uncontrolled pain and unmanageable side effects for many patients whose requests had been denied.

CHICAGO — MET status by immunohistochemistry may predict how patients with osimertinib-treated EGFR-mutated non-small lung cancer will respond to subsequent combination therapy, according to findings presented at ASCO Annual Meeting.Patients with MET-positive status appeared five times as likely as those with MET-negative status to respond to amivantamab (Rybrevant, Janssen) plus lazertinib

CHICAGO — ChatGPT can be used to develop next-generation sequencing reports that outline treatment strategies for patients who have non-small cell lung cancer with driver oncogenes, according to results presented at ASCO Annual Meeting.Investigators from University of Illinois Cancer Center characterized the recommendation relevance as moderate and accuracy as limited (46%, 95% CI,

CHICAGO — The addition of tumor-treating fields to second-line therapy prolonged survival for patients with metastatic non-small cell lung cancer whose disease progressed on or after platinum therapy, according to results presented at ASCO Annual Meeting. Researchers observed no exacerbation in systemic toxicities and reported few high-grade device-related toxicities, results of the

CHICAGO — Adjuvant pembrolizumab showed durable benefit vs. placebo among patients with resected stage IIB or IIC melanoma, according to randomized phase 3 study results presented at ASCO Annual Meeting.After more than 3 years of follow-up, patients assigned the anti-PD-1 therapy achieved significantly longer distant metastasis-free survival (DMFS) and RFS, results of the KEYNOTE-716 trial